Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …

Glypican-1 (GPC1) is one of the six glypican family members in humans. It is composed of a
core protein with three heparan sulfate chains and attached to the cell membrane by a …

Chelator-containing radioimmunoconjugates (RICs) composed of monoclonal antibodies,
chelators, and radiometals exhibit broad potential for cancer diagnosis or therapy. In this …

Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for
about 85% of all primary central nervous system (CNS) tumors. With standard treatment …

Background Glypican 1 (GPC1) is a heparan sulphate proteoglycan cell membrane protein.
It is implicated in driving cancers of the breast, brain, pancreas, and prostate; however, its …

Abstract Glypicans (GPC1-6) are associated with tumorigenic processes and their
involvement in neoplastic behavior has been discussed in different cancer types. Here, a …

Recent studies indicate that Glypican 1 (GPC-1) is aberrantly expressed and plays a key
role in certain cancers, but little is known in the hepatocellular carcinoma. Raw data from …

Highlights•Glypican1 (GPC1) is a molecular biomarker for early-stage cancer
detection.•GPC1 modulated signaling as a co-receptor for FGF, VEGF and TGF-β in cancer …

Radioimmunotherapy (ie, the use of radiolabeled tumor targeting antibodies) is an emerging
approach for the diagnosis, therapy, and monitoring of solid tumors. Often using paired …

A limitation to the wider introduction of personalised dosimetry in theranostics is the relative
paucity of imaging radionuclides with suitable physical and chemical properties to be paired …